{
  "_metadata": {
    "version": "2.1",
    "ticker": "ASND",
    "asset_name": "transcon_cnp_navepegritide"
  },
  "asset": {
    "name": "TransCon_CNP_navepegritide",
    "company": "Ascendis Pharma A/S",
    "ticker": "ASND",
    "target": "C-type natriuretic peptide",
    "mechanism": "Once-weekly TransCon prodrug releasing CNP for continuous exposure",
    "modality": "TransCon prodrug",
    "partner": null,
    "stage": "NDA Submitted",
    "one_liner": "NDA/MAA-accepted once-weekly TransCon CNP (navepegritide) for achondroplasia in children, the only treatment showing benefits beyond height vs placebo in a pivotal trial"
  },
  "target": {
    "name": "NPR-B (Natriuretic Peptide Receptor B)",
    "biology": {
      "simple_explanation": "CNP activates NPR-B receptors on growth plate chondrocytes to counteract the overactive FGFR3 signaling that causes achondroplasia. Navepegritide is the TransCon prodrug form of CNP that provides sustained once-weekly CNP exposure, enabling continuous suppression of the FGFR3 growth brake and promoting more normal long bone growth in children with achondroplasia."
    }
  },
  "clinical_development": {
    "current_stage": "NDA and MAA Accepted",
    "indications_in_development": [
      "Achondroplasia in children aged 2-11",
      "Achondroplasia in infants",
      "Achondroplasia in adolescents",
      "Hypochondroplasia"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    3,
    6,
    16,
    18
  ],
  "_last_extracted": "2026-02-04T13:33:12.100972"
}